ArticleNagoya journal of medical science2025
A retrospective study of post-radiation sarcoma from three institutions in Japan with a review of the literature.
Article in Nagoya journal of medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Characteristics, treatment and survival of patients with chondrosarcoma in five European countries: a DARWIN EU® cohort study.Acta oncologica (Stockholm, Sweden) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated incidence, clinical characteristics, and outcomes of post-radiation sarcoma, a rare but severe complication following radiotherapy. Post-radiation sarcoma is a malignant tumor arising within irradiated areas after a latency period, histologically different from the primary tumor. We retrospectively analyzed cases from January 2000 to January 2025 at three institutions in Japan, employing widely accepted diagnostic criteria. Patient characteristics, treatment details, oncologic outcomes, and prognostic factors were evaluated. Our study included 14 patients with various primary cancers, including three breast cancers, three prostate cancers, and one each of other cancer types. Among the cases, six had osteosarcoma, six had undifferentiated pleomorphic sarcoma, one had chondrosarcoma, and one had malignant peripheral nerve sheath tumor, predominantly occurring in the trunk. The median latency period from last irradiation to diagnosis was 9.9 years (range, 3.0-19.5 years). The median total radiation dose administered before post-radiation sarcoma diagnosis was 52.5 Gy (range, 12-74 Gy). The median overall survival and probability of 5-year overall survival were 2.6 years and 46.8%, respectively. The only factor that tended to correlate with prognosis was whether complete resection was achieved (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.